Advancing oncology and bridging healthcare
gaps
Flatiron Health today announced its significant presence at this
year’s American Society of Clinical Oncology (ASCO) Annual Meeting,
to be held in Chicago this June. Nine abstracts led by Flatiron
have been accepted for poster presentation and online publication.
A comprehensive of all accepted research using Flatiron data
is available via ASCO's website.
Aligned with the conference theme, 'The Art and Science of
Cancer Care: From Comfort to Cure,' Flatiron is dedicated to
spearheading evidence generation in oncology. This year’s accepted
research reflects that dive into critical touch points across the
oncology ecosystem.
“At Flatiron, we're pioneering new approaches to address health
equity, enhance clinical trials, and bridge the gap between routine
care and research,” stated Neal Meropol, VP of Research Oncology,
Flatiron Health. “Through innovative methodologies and real-world
evidence, we're generating insights to improve cancer treatment and
care delivery on behalf of patients. By seamlessly integrating
science, technology, and medicine, we aim to deliver impactful
results in collaboration with our partners.”
This year’s accepted abstracts once again showcase Flatiron’s
commitment to collaboration and partnership in pursuit of its
mission to improve and extend lives by learning from the experience
of every person with cancer.
Highlights include:
- A study employing machine-learning models across a nationwide
cohort to explore practice patterns in the face of chemotherapy
shortages.
- A study exploring the role of biomarkers in guiding treatment
for metastatic breast cancer, focusing specifically on patients
with HR+/HER2- tumors.
- A study examining how structural racism and social determinants
of health contribute to inequities in endometrial cancer care,
particularly among patients with advanced disease.
Schedule a meeting with Flatiron Health at ASCO 2024, and learn
more about our abstracts and events, including workshops and
panels.
Follow Flatiron Health on Twitter and LinkedIn for more updates
and visit us in person at Booth #11123.
Poster Presentations
Impact of carboplatin and cisplatin shortages on treatment
patterns in patients with metastatic solid tumors Emily
Castellanos, Qianyu Yuan, Niquelle Brown Wadé, Khilna Patel,
Catherine Rinaldi, Samantha Reiss, Eunice Hankinson, Aaron Cohen,
Melissa Estevez Abstract #: 11149 Poster Bd #: 344
Real-world ctDNA testing patterns, associated biomarkers and
sites of metastasis in early stage colorectal cancer Erin
Fidyk, Laurynas Kalesinskas, Konstantin Krismer, Auriane Blarre,
Lilia Bouzit, John Ritten, Anca Marinescu, Jonathan Kelly,
Katherine Harrison, Aaron Cohen Abstract #: 3610 Poster Bd #:
273
Testing patterns and prevalence of PIK3CA, AKT1, and PTEN
alterations among patients with HR+/HER2- metastatic breast cancer
in the US Partners: AstraZeneca, Biometrics Oncology, MD
Anderson Cancer Center Leak Park, Samantha Thompson, James Roose,
Yichen Lu, Moumita Chaki, Clara Lam, J. Bryan Lorgulescu Abstract
#: 1041 Poster Bd # 19
Racial/ethnic inequities in care for patients with advanced
endometrial cancer: what’s structural racism and social
determinants of health got to do with it? Cleo A. Ryals, Gene
G. Ho, Khilna Patel, Amy Pierre, Mustafa S. Ascha, Taavy A. Miller,
Olive Mbah Abstract #: 1602 Poster Bd #: 473
The BEV1L study: do real-world outcomes associated with the
addition of bevacizumab to first-line chemotherapy in patients with
ovarian cancer reinforce clinical trial findings? Partners: GSK
and University of Virginia Linda Duska, Jonathan Lim, Tirza Areli
Calderón Boyle, Mark Guinter, Siobhan Halloran, John Hartman,
Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky Abstract
#: 5563 Poster Bd #: 434
Real-world treatment patterns and outcomes by mismatch
repair/microsatellite instability (MMR/MSI) status in patients with
advanced endometrial cancer, 2018-2023 Partners: AstraZeneca,
YU Langone Health, and Washington University School of Medicine
Premal H.Thaker, Bhavana Pothuri, Olga Tymejczyk, Samantha Reiss,
Giovanni Nitti, Theresa Cain, Manila Hada Abstract #: 5601
Poster Bd #: 472
Online Publications
Utility of automated data transfer for cancer clinical
trials Partners: MD Anderson and Washington University in St.
Louis Ivy Altomare, Addison Shelley, Yichen Lu, Paul Salcuni,
Nicole Graves, Abhishek Maiti, Ramaswamy Govindan Abstract:
e23011
Characterization of cancer clinical trials in the community
setting Partners: ACCC, City of Hope, and Penn Lancaster Ivy
Altomare, Yichen Lu, Sumanta Pal, Leigh Boehmer, Latha Shivakumar,
Lyndsey Griffin, Kimberly Demirhan, Molly Kisiel, Randall Oyer
Abstract #: e13506
Treatment inequities in patients with metastatic non-small
cell lung cancer harboring actionable driver oncogenes in the
first-line setting Partners: Flatiron Health, Foundation
Medicine, Genentech, Mary Bird Perkins Cancer Center, New York
Cancer and Blood Specialists, OneOncology, Tennessee Oncology, and
West Cancer Center and Research Institute Gregory Vidal, Thomas
Stricker, Esprit Ma, Elaine Yu, Zhiyu Xia, Daniel Sheinson, Murat
Sincan, Richard Huang, Victor Lin, Richard Zuniga, Neha Jain,
Richard Martin, Davey Daniel Abstract #: e13673
About Flatiron Health
Flatiron Health is a healthtech company expanding the
possibilities for point of care solutions in oncology and using
data for good to power smarter care for every person with cancer.
Through machine learning and AI, real-world evidence, and
breakthroughs in clinical trials, we continue to transform
patients’ real-life experiences into knowledge and create a more
modern, connected oncology ecosystem. Flatiron Health is an
independent affiliate of the Roche Group. Flatiron.com
@FlatironHealth
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523283612/en/
Media Flatiron Health Nina Toor
communications@flatiron.com